Richmond Pharmacology is a frequent contributor and recognised thought leader for various scientific meetings worldwide. See below for a list of past and upcoming events.
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
Richmond Pharmacology will attend AHA Scientific Sessions 2025 in New Orleans, with CEO Dr Jörg Täubel and CSO James Rickard. They will discuss early-phase cardiovascular research, digital endpoints, regulatory engagement, and patient-first strategies.
Richmond Pharmacology will attend The Liver Meeting 2025 in Washington, DC, represented by James Rickard. Key topics include early-phase hepatology trials, non-invasive biomarkers, regulatory strategy, and patient-focused approaches in liver studies.
Richmond Pharmacology will attend BioJapan 2025 in Yokohama, represented by their leadership team. The event focuses on early-phase trials, UK–Japan collaboration, regulatory strategy, bridging studies, and adaptive trial models.
Richmond Pharmacology will attend BioJapan 2025 in Yokohama, represented by their leadership team. The event focuses on early-phase trials, UK–Japan collaboration, regulatory strategy, bridging studies, and adaptive trial models.
Richmond Pharmacology will be present at the ACCP Annual Meeting 2025 in Phoenix, Arizona, with CEO Dr Jörg Täubel and CSO James Rickard. Topics include translational clinical pharmacology, innovative trial design, PK/PD modelling, and regulatory collaboration.
Richmond Pharmacology will attend AHA Hypertension Scientific Sessions 2025 in Baltimore, represented by CEO Dr Jörg Täubel and CSO James Rickard. Discussions will include early-phase hypertension research, BP monitoring, regulatory strategy, and patient-centric design.
Richmond Pharmacology will attend ESC Congress 2025 in Madrid, represented by CEO Dr Jörg Täubel. The team will discuss early-phase cardiovascular and cardiometabolic trials, novel endpoints, risk-stratified study design, accelerated drug development, and patient-focused recruitment.
Richmond Pharmacology will participate in HFA 2025 in Belgrade from 17–20 May, focusing on heart failure research, clinical trials, and scientific collaboration.
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Richmond Pharmacology will attend BioJapan 2025 in Yokohama, represented by their leadership team. The event focuses on early-phase trials, UK–Japan collaboration, regulatory strategy, bridging studies, and adaptive trial models.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.